Med Oncol. 2017 Aug34(8) 132. doi 10.1007/s12032-017-0991-5. Epub 2017 Jun 26.
Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies Sanmei Wang Leopold Sellner Lei Wang Tim Sauer Brigitte Neuber Wenjie Gong Sophia Stock Ming Ni Hao Yao Christian Kleist Anita Schmitt Carsten Müller‑Tidow Michael Schmitt Maria-Luisa Schubert
2018-4-16 · Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic non–small-cell lung cancer (NSCLC) lacking sensitizing EGFR or ALK mutations. Pembrolizumab
11 rows · Medical Oncology (MO) communicates the results of clinical and experimental research in
The Lancet Oncology is the world-leading clinical oncology journal publishing high-quality peer reviewed original research (especially reports from clinical trials) reviews comment and opinion weekly news and Commissions (typically in partnership with societies governments NGOs and academy centres).
2021-2-27 · Med Oncol. 2002 19(2) 71–8 60. Wumkes ML van der Velden AMT Los M Leys MBL Beeker A Nijziel MR et al. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours.
Major Research Areas. Clinical research Advanced radiotherapy techniques intensity modulated radiotherapy stereotactic radiotherapy using tomotherapy cyberknife and autosegmentation nasopharyngeal carcinoma especially its relationship with the Epstein Barr virus and immunotherapy including T cell treatment multimodality treatment that aims at improving control and minimising side
IJMPOIP Int J Med Paediatr Oncol- Print ISSN No -2581-4699 Online ISSN No -2581-4702 IP International Journal of Medical Paediatrics and Oncology (IJMPO) open access peer-reviewed quarterly journal publishing since 2015 and is published under the Khyati Education and Research Foundation (KERF) is registered
Main focuses of interest include Annals of Oncology the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology provides rapid and efficient peer-review publications on innovative cancer treatments or translational work
2018-1-31 · N Engl J Med 377 338-351 2017 Crossref Medline Google Scholar 7. Gravis G Fizazi K Joly F et al Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15) A randomised open-label phase 3 trial. Lancet Oncol 14 149-158 2013 Crossref Medline Google Scholar 8.
2019-6-3 · Abstract Background The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on
Main focuses of interest include Annals of Oncology the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology provides rapid and efficient peer-review publications on innovative cancer treatments or translational work
2017-6-1 · Journal of medical imaging and radiation oncology (ISSN 1754-9477 1754-9485)
Articles from Therapeutic Advances in Medical Oncology are provided here courtesy of SAGE Publications
2021-2-27 · Med Oncol. 2002 19(2) 71–8 60. Wumkes ML van der Velden AMT Los M Leys MBL Beeker A Nijziel MR et al. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours.
Main focuses of interest include Annals of Oncology the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology provides rapid and efficient peer-review publications on innovative cancer treatments or translational work
Gynecologic Oncology is a part of Elsevier s Oncology Journal Network. As part of Article Advance Gynecologic Oncology ensures a fast seamless publication process and offers additional support from a dedicated editorial team. With Gynecologic Oncology indexed in Pubmed/Medline your published article is guaranteed maximum visibility.
2019-1-8 · Lancet Oncol 17 1497-1508 2016 Crossref Medline Google Scholar 18. Gandhi L Rodríguez-Abreu D Gadgeel S et al Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378 2078-2092 2018 Crossref Medline Google Scholar 19.
Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies Sanmei Wang Leopold Sellner Lei Wang Tim Sauer Brigitte Neuber Wenjie Gong Sophia Stock Ming Ni Hao Yao Christian Kleist Anita Schmitt Carsten Müller‑Tidow Michael Schmitt Maria-Luisa Schubert
Latest Impact Factor announced. The latest Impact Factor for Neuro-Oncology has risen to 10.247. To celebrate we have curated a selection of highly cited articles contributing to the new Impact Factor and invite you to explore this collection. Read the collection. Advertisement.
2018-2-14 · Purpose To increase awareness outline strategies and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary multi-organizational panel of experts in medical oncology dermatology gastroenterology rheumatology pulmonology endocrinology urology neurology
The archive for this journal includes Clin Med Insights Oncol Vols. 4 to 15 2010 to 2021 Clin Med Oncol Vols. 2 to 3 2008 to 2009
2018-4-16 · Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic non–small-cell lung cancer (NSCLC) lacking sensitizing EGFR or ALK mutations. Pembrolizumab
Editor s quote. " Journal of Hematology Oncology provides a forum for top-quality research and is a leading title in hematology and oncology with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an
2015-6-21 · SCITHER ADV MED ONCOL THER ADV MED ONCOL(1758-8340)2000-2014 2015(impactfactor)
2019-6-3 · Abstract Background The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on
BQ+ Medical not only produce components for manufacturers all over the world, but also provide private label manufacturing for leading brand distributors in different countries.
8,Cheye Road,Songjiang District,Shanghai 201611 China.
Tel: 86-021-57743953
Email: [email protected]
Copyright © BQ PLUS MEDICAL CO., LTDSitemap | Contact Us |
